Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open‐label phase IIa study and subsequent phase III open‐label extension study

British Journal of Dermatology ◽

10.1111/bjd.19460 ◽

2020 ◽

Cited By ~ 1

Author(s):

M.J. Cork ◽

D. Thaçi ◽

L.F. Eichenfield ◽

P.D. Arkwright ◽

X. Sun ◽

...

Keyword(s):

Atopic Dermatitis ◽

Phase Iii ◽

Extension Study ◽

Severe Atopic Dermatitis ◽

Open Label ◽

Safety And Efficacy ◽

Open Label Extension ◽

Open Label Phase ◽

Subsequent Phase

Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2019.07.074 ◽

2020 ◽

Vol 82 (2) ◽

pp. 377-388 ◽

Cited By ~ 31

Author(s):

Mette Deleuran ◽

Diamant Thaçi ◽

Lisa A. Beck ◽

Marjolein de Bruin-Weller ◽

Andrew Blauvelt ◽

...

Keyword(s):

Atopic Dermatitis ◽

Extension Study ◽

Severe Atopic Dermatitis ◽

Open Label ◽

Phase 3 ◽

Safety And Efficacy ◽

Open Label Extension

Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis: results from a phase II a open‐label trial and subsequent phase III open‐label extension

British Journal of Dermatology ◽

10.1111/bjd.18476 ◽

2019 ◽

Vol 182 (1) ◽

pp. 85-96 ◽

Cited By ~ 22

Author(s):

M.J. Cork ◽

D. Thaçi ◽

L.F. Eichenfield ◽

P.D. Arkwright ◽

T. Hultsch ◽

...

Keyword(s):

Atopic Dermatitis ◽

Phase Ii ◽

Phase Iii ◽

Severe Atopic Dermatitis ◽

Open Label ◽

Open Label Extension ◽

Subsequent Phase ◽

Open Label Trial

103. Long-Term Safety and Efficacy of Certolizumab Pegol in Combination with Methotrexate in the Treatment of Rheumatoid Arthritis: 5-Year Results from a 52-Week Randomized Controlled Trial and Open-Label Extension Study

Rheumatology ◽

10.1093/rheumatology/keu101.024 ◽

2014 ◽

Vol 53 (suppl_1) ◽

pp. i96-i96 ◽

Cited By ~ 1

Author(s):

Edward Keystone ◽

Robert Landewé ◽

Ronald van Vollenhoven ◽

Bernard Combe ◽

Vibeke Strand ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Randomized Controlled Trial ◽

Controlled Trial ◽

Certolizumab Pegol ◽

Extension Study ◽

Open Label ◽

Safety And Efficacy ◽

Randomized Controlled ◽

Open Label Extension

P036 LONG-TERM SAFETY AND EFFICACY OF THE ANTI-MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MADCAM-1) ANTIBODY SHP647 IN ULCERATIVE COLITIS: AN OPEN-LABEL EXTENSION STUDY (TURANDOT II)

Gastroenterology ◽

10.1053/j.gastro.2019.01.088 ◽

2019 ◽

Vol 156 (3) ◽

pp. S25-S26

Author(s):

Walter Reinisch ◽

William J. Sandborn ◽

Silvio Danese ◽

Xavier Hébuterne ◽

Bruce Salzberg ◽

...

Keyword(s):

Ulcerative Colitis ◽

Cell Adhesion ◽

Adhesion Molecule ◽

Cell Adhesion Molecule ◽

Extension Study ◽

Open Label ◽

Safety And Efficacy ◽

Open Label Extension ◽

Cell Adhesion Molecule 1

Long-term treatment of Cushing’s disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial

Endocrine ◽

10.1007/s12020-017-1316-3 ◽

2017 ◽

Vol 57 (1) ◽

pp. 156-165 ◽

Cited By ~ 20

Author(s):

S. Petersenn ◽

L. R. Salgado ◽

J. Schopohl ◽

L. Portocarrero-Ortiz ◽

G. Arnaldi ◽

...

Keyword(s):

Cushing’S Disease ◽

Term Treatment ◽

Phase Iii ◽

Cushing's Disease ◽

Extension Study ◽

Open Label ◽

Phase Iii Trial ◽

Long Term Treatment ◽

Open Label Extension

Long-term safety and efficacy of lumacaftor–ivacaftor therapy in children aged 6–11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study

The Lancet Respiratory Medicine ◽

10.1016/s2213-2600(20)30517-8 ◽

2021 ◽

Author(s):

Mark A Chilvers ◽

Jane C Davies ◽

Carlos Milla ◽

Simon Tian ◽

Zifei Han ◽

...

Keyword(s):

Cystic Fibrosis ◽

Extension Study ◽

Open Label ◽

Phase 3 ◽

Safety And Efficacy ◽

Open Label Extension

MP31-01 LONG-TERM SAFETY AND EFFICACY OF SER120 1.5 MCG IN PATIENTS WITH NOCTURIA: RESULTS FROM A 2-YEAR OPEN-LABEL EXTENSION STUDY

The Journal of Urology ◽

10.1016/j.juro.2017.02.955 ◽

2017 ◽

Vol 197 (4S) ◽

Author(s):

Scott MacDiarmid ◽

J.P. Nicandro ◽

Maria Cheng ◽

Steven Abrams ◽

Seymour Fein ◽

...

Keyword(s):

Extension Study ◽

Open Label ◽

Safety And Efficacy ◽

Open Label Extension

Long-Term Safety and Efficacy of a Once-Daily Formulation of Alfuzosin 10 mg in Patients with Symptomatic Benign Prostatic Hyperplasia: Open-Label Extension Study

European Urology ◽

10.1016/s0302-2838(01)00016-1 ◽

2002 ◽

Vol 41 (1) ◽

pp. 54-61 ◽

Cited By ~ 43

Author(s):

P van Kerrebroeck ◽

A Jardin ◽

P van Cangh ◽

K.U Laval

Keyword(s):

Benign Prostatic Hyperplasia ◽

Prostatic Hyperplasia ◽

Extension Study ◽

Open Label ◽

Symptomatic Benign Prostatic Hyperplasia ◽

Once Daily ◽

Safety And Efficacy ◽

Open Label Extension

Abobotulinumtoxin A in children with lower limb spasticity due to cerebral palsy: Safety and efficacy results of a Phase III open-label extension study

Gait & Posture ◽

10.1016/j.gaitpost.2016.07.275 ◽

2016 ◽

Vol 49 ◽

pp. 222

Keyword(s):

Cerebral Palsy ◽

Lower Limb ◽

Phase Iii ◽

Extension Study ◽

Open Label ◽

Safety And Efficacy ◽

Open Label Extension ◽

Limb Spasticity ◽

Lower Limb Spasticity

Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study

The Lancet Respiratory Medicine ◽

10.1016/s2213-2600(21)00322-2 ◽

2021 ◽

Author(s):

Michael E Wechsler ◽

Linda B Ford ◽

Jorge F Maspero ◽

Ian D Pavord ◽

Alberto Papi ◽

...

Keyword(s):

Severe Asthma ◽

Extension Study ◽

Open Label ◽

Safety And Efficacy ◽

Open Label Extension